DiagnosTear Technologies Inc is an ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. Its TeaRx technology is a diagnostic platform intended for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of non-invasively collected tear fluid. The first CE-IVD and Israeli MoH-approved test based on the TeaRx platform is intended for diagnosis of Dry Eye Syndrome. This product is not FDA-cleared yet. Beyond DES, It is developing innovative tests based on the TeaRx platform for additional ophthalmic indications. Its pipeline includes TeaRx Red Eye; The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis.
No Data